NetraMark and CAMH Announce Research Award to Advance AI-Driven Discovery in Schizophrenia and Depression

Core Insights - NetraMark Holdings Inc. has been awarded the Ontario Research Fund - Research Excellence Award in collaboration with the Centre for Addiction and Mental Health (CAMH) for their innovative partnership in advancing research and technology in mental health [1][2]. Group 1: Collaboration and Research Focus - The collaboration will utilize NetraAI, a machine learning platform, to analyze genetic and epigenetic data from studies on schizophrenia and major depressive disorder [2][3]. - The initiative aims to identify explainable patient subpopulations to clarify biological subtypes in psychiatric disorders, supporting next-generation precision treatment strategies [3]. Group 2: Technological Advancements - NetraAI is designed to separate small datasets into explainable and unexplainable subsets, enhancing the accuracy of insights derived from clinical trials [6]. - The platform's unique focus mechanisms aim to reduce the risk of overfitting, which can lead to inaccurate insights and improve the chances of clinical trial success [6]. Group 3: Impact on Clinical Trials - The collaboration is expected to enhance NetraAI's capabilities to serve pharmaceutical sponsors, ultimately improving clinical trial outcomes in the psychiatric space [3][4]. - The research will also evaluate additional datasets from the Ontario Health Insurance Plan (OHIP) to analyze cost-effectiveness and the broader health-system impact of personalized patient care [4]. Group 4: Institutional Background - CAMH is recognized as Canada's largest mental health and addiction teaching hospital, combining clinical care, research, education, and policy development to transform the lives of individuals affected by mental illness [5]. - The partnership with CAMH allows NetraMark to leverage extensive genomic and clinical datasets to explore genetic influences on treatment responses [4]. Group 5: Company Overview - NetraMark focuses on developing Generative Artificial Intelligence and Machine Learning solutions specifically for the pharmaceutical industry, utilizing a novel algorithm to parse patient data effectively [7]. - The company's approach enables accurate segmentation of diseases and classification of patients based on treatment sensitivity and efficacy [7].